Sichuan Biokin Pharmaceutical (688506.SH): Yizekang included in the breakthrough therapy designation list

Sichuan Biokin Pharmaceutical (688506.SH) announced that Yizekang (lunvomab vedotin, BL-B01D1/iza-bren), the company's globally first-in-class, novel-concept, and the world's first and only approved EGFRHER3 bispecific antibody-drug conjugate (ADC), for the treatment of patients with recurrent or metastatic biliary tract cancer who have failed prior platinum-containing chemotherapy, has been included in the breakthrough therapy designation list by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, and the public notice was completed recently. To date, 9 indications of Yizekang have been included in the CDE's breakthrough therapy designation list, and 1 indication has been granted breakthrough therapy designation by the U.S. Food and Drug Administration.